Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.

Gene transfer methodologies are being explored as strategies to restore and preserve neuronal function in Parkinson's Disease. This technology represents a new therapeutic modality, holding promise for continuous and localized delivery, of neuroprotective molecules. Two primary approaches for gene transfer have emerged: in vivo and ex vivo. Recent advances in the construction and characterization of gene transfer vectors have generated more efficient vehicles to deliver and express candidate therapeutic genes. Direct gene transfer into the CNS can be achieved with replication-deficient viral vectors of several types: adenovirus, adeno-associated virus, and herpes simplex virus. These vector systems are being evaluated in models of Parkinson's disease. Strategies to deliver genes include those that either augment dopamine biosynthesis or attenuate loss of dopaminergic neurons. A discussion of the various approaches is detailed.

• Publication year

  1997

• Venue

  Experimental Neurology

• Publication date

  1997-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/EXNR.1996.6389PMID 9126153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Astrocytes infected with replication-defective adenovirus containing a secreted form of CNTF or NT3 show enhanced support of neuronal populations in vitro.

  1996cited by this paper
• Prolonged In Vivo Gene Expression Driven by a Tyrosine Hydroxylase Promoter in a Defective Herpes Simplex Virus Amplicon Vector

  1996cited by this paper
• Functional recovery in parkinsonian monkeys treated with GDNF

  1996cited by this paper
• Defective HSV-1 Vector Expressing BDNF in Auditory Ganglia Elicits Neurite Outgrowth: Model for Treatment of Neuron Loss Following Cochlear Degeneration

  1996cited by this paper
• Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system.

  1996cited by this paper
• In vivo model of adeno-associated virus vector persistence and rescue

  1996cited by this paper
• PET studies of the striatal dopaminergic system in Parkinson's disease (PD).

  1995cited by this paper
• Adenoviral-Mediated Gene Transfer: Potential Therapeutic Applications

  1995cited by this paper
• Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

  1995cited by this paper
• Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

  1995cited by this paper
• Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease.

  1995cited by this paper
• Temporal pattern of internucleosomal DNA fragmentation in the striatum and hippocampus after transient forebrain ischemia.

  1995cited by this paper
• Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss.

  1995cited by this paper
• Genetics and Biology of Adeno-Associated Virus

  1995cited by this paper
• Gene therapy and the brain.

  1995cited by this paper
• Role of BCL-2 in the survival and function of developing and mature sympathetic neurons.

  1995cited by this paper
• Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis

  1995cited by this paper
• TGF‐beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity.

  1995cited by this paper
• Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat.

  1995cited by this paper
• Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia.

  1995cited by this paper
• Viral vectors : gene therapy and neuroscience applications

  1995cited by this paper
• Neural transplantation of cells expressing the anti-apoptotic gene bcl-2.

  1995cited by this paper
• Herpes Simplex Virus Type 1 Amplicon Vectors with Glucocorticoid-Inducible Gene Expression

  1995cited by this paper
• Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain

  1995cited by this paper
• Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector.

  1994cited by this paper
• Neurotrophic‐4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures

  1994cited by this paper
• A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats

  1994cited by this paper
• Characterization of apoptosis in cultured rat sympathetic neurons after nerve growth factor withdrawal

  1994cited by this paper
• Transfer of the nerve growth factor gene into cell lines and cultured neurons using a defective herpes simplex virus vector. Transfer of the NGF gene into cells by a HSV-1 vector.

  1994cited by this paper
• Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy

  1994cited by this paper
• Neural-targeted gene therapy for rodent and primate hemiparkinsonism.

  1994cited by this paper
• Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease

  1994cited by this paper
• Direct plasmid mediated transfection of adult murine brain cells in vivo using cationic liposomes.

  1994cited by this paper
• Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

  1994cited by this paper
• Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia.

  1994cited by this paper
• Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

  1994cited by this paper
• Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase

  1994cited by this paper
• Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function

  1994cited by this paper
• Gene transfer to brain using herpes simplex virus vectors

  1994cited by this paper
• Expression of GDNF mRNA in rat and human nervous tissue.

  1994cited by this paper
• Dopaminergic neurons in rat ventral midbrain express brain‐derived neurotrophic factor and neurotrophin‐3 mRNAs

  1994cited by this paper
• Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.

  1994cited by this paper
• The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra.

  1994cited by this paper
• Efficacy of Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 on Neurochemical and Behavioral Deficits Associated with Partial Nigrostriatal Dopamine Lesions

  1994cited by this paper
• Multiple astrocyte transcripts encode nigral trophic factors in rat and human.

  1994cited by this paper
• Particle Bombardment-Mediated Gene Transfer and Expression in Rat Brain Tissues

  1993cited by this paper
• Apoptosis (the 1992 Frank Rose Memorial Lecture).

  1993cited by this paper
• BCL-2 blocks glutamate toxicity in neural cell lines.

  1993cited by this paper
• bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

  1993cited by this paper
• Bcl-2 affects survival but not neuronal differentiation of PC12 cells

  1993cited by this paper
• Transfer of a foreign gene into the brain using adenovirus vectors

  1993cited by this paper
• An adenovirus vector for gene transfer into neurons and glia in the brain

  1993cited by this paper
• Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1–deleted adenoviruses

  1993cited by this paper
• bcl-2 inhibits death of central neural cells induced by multiple agents.

  1993cited by this paper
• Decreased reporter gene expression during latent infection with HSV LAT promoter constructs.

  1993cited by this paper
• A model system for in vivo gene transfer into the central nervous system using an adenoviral vector

  1993cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species.

  1993cited by this paper
• Glial Cell Line-Derived Neurotrophic Factor Is Expressed in the Developing but Not Adult Striatum and Stimulates Developing Dopamine Neurons in Vivo

  1993cited by this paper
• Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection.

  1993cited by this paper
• Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors

  1993cited by this paper
• The Protooncogene bcl‐2 Inhibits Apoptosis in PC12 Cells

  1993cited by this paper
• Pharmacotherapy of Parkinson's disease: Research from 1960 to 1991

  1993cited by this paper
• The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis.

  1993cited by this paper
• In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment.

  1993cited by this paper
• Persistence of plasmid DNA and expression in rat brain cells in vivo.

  1992cited by this paper
• Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain

  1992cited by this paper
• Neurotoxicity and neuroprotection in Parkinson's disease.

  1992cited by this paper
• Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene.

  1992cited by this paper
• Modulation of the cellular phenotype by integrated adeno-associated virus.

  1992cited by this paper
• Gene Transfer into Mammalian Central Nervous System Using Herpes Virus Vectors: Extended Expression of Bacterial lacZ in Neurons Using the Neuron-Specific Enolase Promoter

  1992cited by this paper
• Occupational and environmental causes of parkinsonism.

  1992cited by this paper
• In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer.

  1992cited by this paper
• Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia.

  1992cited by this paper
• Herpesvirus vector gene transfer and expression of β–glucuronidase in the central nervous system of MRS VII mice

  1992cited by this paper
• In Vivo Expression of β-Galactosidase in Hippocampal Neurons by HSV-Mediated Gene Transfer

  1992cited by this paper
• Characteristics of Dopaminergic Neurotoxicity Produced by MPTP and Methamphetamine a

  1992cited by this paper
• Overview of Parkinson's Disease

  1992cited by this paper
• Dopaminergic stimulation up‐regulates the in vivo expression of brain‐derived neurotrophic factor (BDNF) in the striatum

  1992cited by this paper
• BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra

  1991cited by this paper
• Herpes simplex virus for gene delivery to neurons.

  1991cited by this paper
• Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells.

  1990cited by this paper
• A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons.

  1990cited by this paper
• An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.

  1990cited by this paper
• Regional distribution of brain‐derived neurotrophic factor mRNA in the adult mouse brain.

  1990cited by this paper
• A prominent serine-rich region in Vmw175, the major transcriptional regulator protein of herpes simplex virus type 1, is not essential for virus growth in tissue culture.

  1990cited by this paper
• Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase.

  1990cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Identification of the latency-associated transcript promoter by expression of rabbit beta-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus

  1989cited by this paper
• Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

  1989cited by this paper
• A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons.

  1988cited by this paper
• The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease.

  1987cited by this paper
• Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides.

  1987cited by this paper
• Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4

  1985cited by this paper
• The herpes simplex virus amplicon: analyses of cis-acting replication functions.

  1985cited by this paper
• Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis

  1984cited by this paper
• Periodic transcription of yeast histone genes.

  1982cited by this paper
• The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector.

  1982cited by this paper
• Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.

  1980cited by this paper
• Cell death: the significance of apoptosis.

  1980cited by this paper

• Current Treatments and New, Tentative Therapies for Parkinson’s Disease

  2023cites this paper
• Exploring the role of gene therapy for neurological disorders.

  2020cites this paper
• Localised non-viral delivery of nucleic acids for nerve regeneration in injured nervous systems.

  2019cites this paper
• 4.33 Engineering Viruses For Gene Therapy

  2017cites this paper
• Mitochondria: A Therapeutic Target for Parkinson’s Disease?

  2015cites this paper
• La vitamina D regula la expresión del factor neurotrófico GDNF en cultivos neuronales estriatales y en ratas normales y hemiparkinsonianas

  2014cites this paper
• Dual Modified Liposomes for Drug and Gene Delivery to Brain

  2014cites this paper
• Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection.

  2013cites this paper
• The function and mechanisms of Nurr1 action in midbrain dopaminergic neurons, from development and maintenance to survival.

  2012cites this paper
• 2.202 – Engineering Viruses For Gene Therapy

  2011cites this paper
• RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain.

  2011cites this paper
• Gene regulatory networks in embryonic stem cells and brain development.

  2009influential citation
• PREFACE: What Do You Mean by “Translational Research”? An Enquiry Through Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

  2008cites this paper
• Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons

  2008cites this paper
• Potentials of ES cell therapy in neurodegenerative diseases.

  2008cites this paper
• Gazing into the future: Parkinson's disease gene therapeutics to modify natural history.

  2008cites this paper
• Neurotrophic factors as a therapeutic target for Parkinson's disease

  2008cites this paper
• Nonviral Approaches for Neuronal Delivery of Nucleic Acids

  2007cites this paper
• GDNF delivery for Parkinson's disease.

  2007cites this paper
• Étude des mécanismes d’actions de la stimulation électrique haute fréquence utilisée comme traitement de la maladie de Parkinson.

  2007cites this paper
• Progress and Challenges in Immunoisolation for CNS Cell Therapy

  2006cites this paper
• Étude des effets de la stimulation électrique à haute fréquence dans un modèle cellulaire in vitro

  2005cites this paper
• Intraparenchymal delivery of GDNF towards a treatment for Parkinson ’ s disease Review Article

  2004cites this paper
• Neuroprotective Effects of Encapsulated CNTF-Producing Cells in a Rodent Model of Huntington's Disease are Dependent on the Proximity of the Implant to the Lesioned Striatum1

  2004cites this paper
• Iris pigment epithelial cells: a possible cell source for the future treatment of neurodegenerative diseases.

  2004cites this paper
• Altering behavior with gene transfer in the limbic system.

  2003cites this paper
• Convergent Pathobiologic Model of Parkinson's Disease

  2003cites this paper
• Adeno-Associated Viral Delivery of GDNF Promotes Recovery of Dopaminergic Phenotype following a Unilateral 6-Hydroxydopamine Lesion

  2002cites this paper
• Models of repair mechanisms for future treatment modalities of Parkinson's disease.

  2002cites this paper
• Actualités sur les traitements de la maladie de Parkinson

  2002cites this paper
• Enhanced Vascularization and Survival of Neural Transplants with Ex Vivo Angiogenic Gene Transfer

  2002cites this paper
• Immunoisolation cell therapy for CNS diseases.

  2001cites this paper
• Update on Immunoisolation Cell Therapy for CNS Diseases

  2001cites this paper
• Gene therapy in the CNS

  2000cites this paper
• Intracerebral Gene Transfer Using Viral Vectors

  2000cites this paper
• Neurotrophic factors in Alzheimer's and Parkinson's disease brain.

  2000cites this paper
• Cell delivery to the central nervous system.

  2000cites this paper
• Strategies for Administering Neurotrophic Factors to the Central Nervous System

  1999cites this paper
• Neuroprotective therapies.

  1999cites this paper
• Gene Transfer to the Nigrostriatal System by Hybrid Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors

  1999cites this paper
• Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors.

  1999cites this paper
• The role of neuronal growth factors in neurodegenerative disorders of the human brain.

  1998cites this paper
• Prospects for new drug treatment in idiopathic parkinsonism

  1998cites this paper
• Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex.

  1998cites this paper
• Regeneration in the central nervous system: Pharmacological intervention, xenotransplantation, and stem cell transplantation

  1998cites this paper
• Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor

  1998cites this paper
• Gene transfer and delivery in central nervous system disease.

  1997cites this paper